Tag

M&A

4 stories

Deals Jun 10, 2026

Lilly Bought 10, Spent $25B: More Than Pharma Combined

Lilly's $25.27B deal spree in 2026 eclipses the combined M&A of every other top-12 pharma, and the obesity juggernaut isn't done yet.

Deals Apr 18, 2026

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy

UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.

Deals Apr 8, 2026

Gilead Spends $14.77B on Three Deals, Then Hits Pause

Gilead bought Arcellx, Ouro, and Tubulis for $14.77B in under ten weeks. CFO says further big deals are unlikely this year, but the door stays open.

FDA Apr 8, 2026

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.